Pro-inflammatory cytokines, such as TNF or IL12A, the T-cell activation molecule CD28, the regulatory molecules IL10, TGFB1 or the adhesion molecules ITGA4 and ITGB1 have all been evaluated previously as therapeutic targets for autoimmune diseases, including MS [24]–[29]. The gene discussed is TNF; the disease is myeloid sarcoma.